glp 1 drugs medicaid Pennsylvania stopped covering GLP-1s for obesity this year, but it's not all savings Rhode Island considers ending Medicaid

Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis

It is widely studied for its regenerative and healing properties

2.5 Caffeine in (autoimmune) hepatitis Hepatitis is a general term for liver inflammation, which usually refers to liver cells destroyed by various pathogenic factors, such as viruses, bacteria, parasites, chemicals, poisons, drugs, alcohol, and autoimmune factors

Retatrutide needs additional TRIUMPH trial results throughout 2026 before submitting for FDA approval in late 2026 or early 2027, with approval expected in late 2027 and launch in early 2028